Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

PURPOSE: We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kummar, Shivaani, Kinders, Robert, Gutierrez, Martin E., Rubinstein, Larry, Parchment, Ralph E., Phillips, Lawrence R., Ji, Jiuping, Monks, Anne, Low, Jennifer A., Chen, Alice, Murgo, Anthony J., Collins, Jerry, Steinberg, Seth M., Eliopoulos, Helen, Giranda, Vincent L., Gordon, Gary, Helman, Lee, Wiltrout, Robert, Tomaszewski, Joseph E., Doroshow, James H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2739635/
https://ncbi.nlm.nih.gov/pubmed/19364967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.7681
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados